RESUMO
OBJECTIVE: To investigate the relationship between C-reactive protein and albumin ratios (CAR) and all-cause and cardiovascular disease(CVD)-specific mortality in individuals with coronary heart disease(CHD). METHODS: The data from 1895 patients were extracted from the National Health and Nutrition Examination Survey (NHANES) database from 1999-2010. We used weighted COX regression analyses to explore the association between CAR, all-cause, and CVD-specific mortality. Restricted cubic spline(RCS) regression models and threshold effects analysis were used to analyze nonlinear relationships. Subgroup analyses were also performed to explore these relationships further. RESULTS: During a mean follow-up of 115.78 months, 61.48% of deaths occurred, and 21.85% were due to CVD. After adjusting for potential confounders, each 1-unit increase in CAR was associated with a 65% increase in all-cause mortality and a 67% increase in CVD-specific mortality. The RCS model revealed a non-linear association between CAR and the risk of all-cause mortality and CVD-specific mortality in CHD patients (all non-linear P < 0.001). Threshold effects analysis identified inflection points in regression models of all-cause mortality (0.04, P < 0.001) and CVD-specific mortality (0.05, P = 0.0024). The interaction tests found sex, smoking and diabetes influenced the association between CAR and all-cause mortality and sex, smoking and HF influenced its association with CVD-specific mortality (all P < 0.05). CONCLUSION: There was a nonlinear association between CAR and all-cause mortality and CVD mortality in patients with CHD, with a higher hazard ratio before the inflection point. Sex, smoking, diabetes, and HF might have an effect on the associations between CAR and death risks.
Assuntos
Doença das Coronárias , Inquéritos Nutricionais , Humanos , Masculino , Feminino , Estudos Retrospectivos , Doença das Coronárias/mortalidade , Pessoa de Meia-Idade , Idoso , Proteína C-Reativa/análise , Doenças Cardiovasculares/mortalidade , Albumina Sérica/análise , Fatores de Risco , AdultoRESUMO
BACKGROUND: Numerous studies have linked fine particulate matter (PM2.5) to increased cardiovascular mortality. Less is known how the PM2.5-cardiovascular mortality association varies by use of cardiovascular medications. This study sought to quantify effect modification by statin use status on the associations between long-term exposure to PM2.5 and mortality from any cardiovascular cause, coronary heart disease (CHD), and stroke. METHODS: In this nested case-control study, we followed 1.2 million community-dwelling adults aged ≥66 years who lived in Ontario, Canada from 2000 through 2018. Cases were patients who died from the three causes. Each case was individually matched to up to 30 randomly selected controls using incidence density sampling. Conditional logistic regression models were used to estimate odds ratios (ORs) for the associations between PM2.5 and mortality. We evaluated the presence of effect modification considering both multiplicative (ratio of ORs) and additive scales (the relative excess risk due to interaction, RERI). RESULTS: Exposure to PM2.5 increased the risks for cardiovascular, CHD, and stroke mortality. For all three causes of death, compared with statin users, stronger PM2.5-mortality associations were observed among non-users [e.g. for cardiovascular mortality corresponding to each interquartile range increase in PM2.5, OR = 1.042 (95% CI, 1.032-1.053) vs OR = 1.009 (95% CI, 0.996-1.022) in users, ratio of ORs = 1.033 (95% CI, 1.019-1.047), RERI = 0.039 (95% CI, 0.025-0.050)]. Among users, partially adherent users exhibited a higher risk of PM2.5-associated mortality than fully adherent users. CONCLUSIONS: The associations of chronic exposure to PM2.5 with cardiovascular and CHD mortality were stronger among statin non-users compared to users.
Assuntos
Doenças Cardiovasculares , Inibidores de Hidroximetilglutaril-CoA Redutases , Material Particulado , Humanos , Material Particulado/efeitos adversos , Material Particulado/análise , Masculino , Idoso , Feminino , Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos , Estudos de Casos e Controles , Ontário/epidemiologia , Doenças Cardiovasculares/mortalidade , Idoso de 80 Anos ou mais , Doença das Coronárias/mortalidade , Doença das Coronárias/epidemiologia , Acidente Vascular Cerebral/mortalidade , Acidente Vascular Cerebral/epidemiologia , Exposição Ambiental/efeitos adversos , Modelos Logísticos , Fatores de Risco , Vida Independente , Razão de ChancesRESUMO
BACKGROUND: Cancer, coronary heart disease, dementia, and stroke are major contributors to morbidity and mortality in England. We aimed to assess the economic burden (including health-care, social care, and informal care costs, as well as productivity losses) of these four conditions in England in 2018, and forecast this cost to 2050 using population projections. METHODS: We used individual patient-level data from the Clinical Practice Research Datalink (CPRD) Aurum, which contains primary care electronic health records of patients from 738 general practices in England, to calculate health-care and residential and nursing home resource use, and data from the English Longitudinal Study on Ageing (ELSA) to calculate informal and formal care costs. From CPRD Aurum, we included patients registered on Jan 1, 2018, in a CPRD general practice with Hospital Episode Statistics (HES)-linked records, omitting all children younger than 1 year. From ELSA, we included data collected from wave 9 (2018-19). Aggregate English resource use data on morbidity, mortality, and health-care, social care, and informal care were obtained and apportioned, using multivariable regression analyses, to cancer, coronary heart disease, dementia, and stroke. FINDINGS: We included 4 161 558 patients from CPRD Aurum with HES-linked data (mean age 41 years [SD 23], with 2 079 679 [50·0%] men and 2 081 879 [50·0%] women) and 8736 patients in ELSA (68 years [11], with 4882 [55·9 %] men and 3854 [44·1%] women). In 2018, the total cost was £18·9 billion (95% CI 18·4-19·4) for cancer, £12·7 billion (12·3-13·0) for coronary heart disease, £11·7 billion (9·6-12·7) for dementia, and £8·6 billion (8·2-9·0) for stroke. Using 2050 English population projections, we estimated that costs would rise by 40% (39-41) for cancer, 54% (53-55) for coronary heart disease, 100% (97-102) for dementia, and 85% (84-86) for stroke, for a total of £26·5 billion (25·7-27·3), £19·6 billion (18·9-20·2), £23·5 billion (19·3-25·3), and £16·0 billion (15·3-16·6), respectively. INTERPRETATION: This study provides contemporary estimates of the wide-ranging impact of the most important chronic conditions on all aspects of the economy in England. The data will help to inform evidence-based polices to reduce the impact of chronic disease, promoting care access, better health outcomes, and economic sustainability. FUNDING: Alzheimer's Research UK.
Assuntos
Doença das Coronárias , Efeitos Psicossociais da Doença , Demência , Neoplasias , Acidente Vascular Cerebral , Humanos , Inglaterra/epidemiologia , Demência/economia , Demência/epidemiologia , Feminino , Masculino , Neoplasias/economia , Neoplasias/epidemiologia , Neoplasias/mortalidade , Doença das Coronárias/economia , Doença das Coronárias/epidemiologia , Doença das Coronárias/mortalidade , Acidente Vascular Cerebral/economia , Acidente Vascular Cerebral/epidemiologia , Acidente Vascular Cerebral/mortalidade , Idoso , Pessoa de Meia-Idade , Estudos de Coortes , Custos de Cuidados de Saúde/estatística & dados numéricos , Custos de Cuidados de Saúde/tendências , Adulto , Estudos Longitudinais , Idoso de 80 Anos ou maisRESUMO
Prior studies have examined rural-urban disparities in access to cardiac rehabilitation (CR). However, few have examined the relationship between disparate access to CR and cardiovascular disease outcomes in rural areas. In this analysis of 1975 nonmetro United States counties, we investigated the relationship between number of hospitals with CR and Medicare-population hospitalization rates (per 1000 adults ≥65 years) and county-population mortality rates (per 100,000 adults ≥18 years) due to coronary heart disease (CHD), heart failure (HF), or stroke, using multivariable linear-regression-modeling adjusting for socio-demographic and comorbid conditions. Median CHD hospitalization (13.0 vs. 12.2), HF hospitalization (16.1 vs. 13.3), HF death (114.2 vs. 110.9), stroke hospitalization (12.0 vs. 10.9), and stroke death (39.6 vs. 37.1) rates were higher in nonmetro counties without versus with a CR facility (p-values< 0.001). There were inverse correlations between number of hospitals with CR and CHD (r= -0.161), HF (r= -0.261) and stroke (r= -0.237) hospitalization rates, and stroke mortality (r= -0.144) rates (p-values< 0.001). After adjustment, as the number of hospitals with CR increased, there were decreases in hospitalization rates of 1.78 for CHD, 7.20 for HF, and 2.43 for stroke, per 1000 in the population (p-values < 0.001) and decreases in stroke deaths of 9.17 per 100,000 in the population (p= 0.02). Access to hospitals with CR in US nonmetro counties is inversely related to CHD, HF, and stroke hospitalization, and stroke mortality. Our findings call for reducing barriers to CR in nonmetro communities and further exploring the relationship between CR and stroke outcomes.
Assuntos
Acessibilidade aos Serviços de Saúde , Hospitalização , População Rural , Humanos , Estados Unidos/epidemiologia , Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Masculino , Feminino , Idoso , População Rural/estatística & dados numéricos , Hospitalização/estatística & dados numéricos , Acidente Vascular Cerebral/epidemiologia , Acidente Vascular Cerebral/mortalidade , Reabilitação Cardíaca/estatística & dados numéricos , Reabilitação Cardíaca/métodos , Insuficiência Cardíaca/epidemiologia , Insuficiência Cardíaca/reabilitação , Insuficiência Cardíaca/mortalidade , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/mortalidade , Disparidades em Assistência à Saúde/estatística & dados numéricos , Medicare/estatística & dados numéricos , Doença das Coronárias/reabilitação , Doença das Coronárias/mortalidade , Doença das Coronárias/epidemiologia , Idoso de 80 Anos ou maisRESUMO
Major depressive disorder is a well-established risk factor for cardiac events in patients with coronary heart disease, but clinical trials have produced little evidence that treating depression reliably improves cardiac event-free survival in these patients. In this review, we offer evidence that certain symptoms that commonly remain after otherwise successful treatment of depression-insomnia, fatigue, and anhedonia-independently predict cardiac events. This may help to explain the failure of previous depression treatment trials to improve cardiac event-free survival even when other symptoms of depression improve. We thus propose that adverse cardiovascular effects that have long been attributed to syndromal depression may be instead caused by persistent fatigue, insomnia, and anhedonia, regardless of whether other symptoms of depression are present. We also identify interventions for these symptoms and call for more research to evaluate their effectiveness in depressed patients with coronary heart disease.
Assuntos
Doença das Coronárias , Humanos , Doença das Coronárias/psicologia , Doença das Coronárias/mortalidade , Doença das Coronárias/complicações , Transtorno Depressivo Maior/psicologia , Transtorno Depressivo Maior/terapia , Antidepressivos/uso terapêutico , Depressão/terapiaRESUMO
BACKGROUND: The well-established inverse relationship between socioeconomic status (SES) and risk of developing coronary heart disease (CHD) cannot be explained solely by differences in traditional risk factors. OBJECTIVE: To model the role SES plays in the burden of premature CHD in Argentina. MATERIALS AND METHODS: We used the Cardiovascular Disease Policy Model-Argentina to project incident CHD events and mortality in low and high-SES Argentinean adults 35 to 64 years of age from 2015 to 2024. Using data from the 2018 National Risk Factor Survey, we defined low SES as not finishing high-school and/or reporting a household income in quintiles 1 or 2. We designed simulations to apportion CHD outcomes in low SES adults to: (1) differences in the prevalence of traditional risk factors between low and high SES adults; (2) nontraditional risk associated with low SES status; (3) preventable events if risk factors were improved to ideal levels; and (4) underlying age- and sex-based risk. RESULTS: 56% of Argentina´s 35- to 64-year-old population has low SES. Both high and low SES groups have poor control of traditional risk factors. Compared with high SES population, low SES population had nearly 2-fold higher rates of incident CHD and CHD deaths per 10 000 person-years (incident CHD: men 80.8 [95%CI 76.6-84.9] vs 42.9 [95%CI 37.4-48.1], women 39.0 [95%CI 36.-41.2] vs 18.6 [95%CI 16.3-20.9]; CHD deaths: men 10.0 [95%CI 9.5-10.5] vs 6.0 [95%CI 5.6-6.4], women 3.2 [95%CI 3.0-3.4] vs 1.8 [95%CI 1.7-1.9]). Nontraditional low SES risk accounts for 73.5% and 70.4% of the event rate gap between SES levels for incident CHD and CHD mortality rates, respectively. DISCUSSION: CHD prevention policies in Argentina should address contextual aspects linked to SES, such as access to education or healthcare, and should also aim to implement known clinical strategies to achieve better control of CHD risk factors in all socioeconomic levels.
Assuntos
Doença das Coronárias , Classe Social , Humanos , Argentina/epidemiologia , Adulto , Pessoa de Meia-Idade , Masculino , Feminino , Doença das Coronárias/epidemiologia , Doença das Coronárias/mortalidade , Fatores de Risco , Prevalência , Baixo Nível SocioeconômicoRESUMO
BACKGROUND: The incidence of myocardial infarction (MI) and sudden cardiac death (SCD) is significantly higher in individuals with Type 2 Diabetes Mellitus (T2DM) than in the general population. Strategies for the prevention of fatal arrhythmias are often insufficient, highlighting the need for additional non-invasive diagnostic tools. The T-wave heterogeneity (TWH) index measures variations in ventricular repolarization and has emerged as a promising predictor for severe ventricular arrhythmias. Although the EMPA-REG trial reported reduced cardiovascular mortality with empagliflozin, the underlying mechanisms remain unclear. This study investigates the potential of empagliflozin in mitigating cardiac electrical instability in patients with T2DM and coronary heart disease (CHD) by examining changes in TWH. METHODS: Participants were adult outpatients with T2DM and CHD who exhibited TWH > 80 µV at baseline. They received a 25 mg daily dose of empagliflozin and were evaluated clinically including electrocardiogram (ECG) measurements at baseline and after 4 weeks. TWH was computed from leads V4, V5, and V6 using a validated technique. The primary study outcome was a significant (p < 0.05) change in TWH following empagliflozin administration. RESULTS: An initial review of 6,000 medical records pinpointed 800 patients for TWH evaluation. Of these, 412 exhibited TWH above 80 µV, with 97 completing clinical assessments and 90 meeting the criteria for high cardiovascular risk enrollment. Empagliflozin adherence exceeded 80%, resulting in notable reductions in blood pressure without affecting heart rate. Side effects were generally mild, with 13.3% experiencing Level 1 hypoglycemia, alongside infrequent urinary and genital infections. The treatment consistently reduced mean TWH from 116 to 103 µV (p = 0.01). CONCLUSIONS: The EMPATHY-HEART trial preliminarily suggests that empagliflozin decreases heterogeneity in ventricular repolarization among patients with T2DM and CHD. This reduction in TWH may provide insight into the mechanism behind the decreased cardiovascular mortality observed in previous trials, potentially offering a therapeutic pathway to mitigate the risk of severe arrhythmias in this population. TRIAL REGISTRATION: NCT: 04117763.
Assuntos
Compostos Benzidrílicos , Diabetes Mellitus Tipo 2 , Glucosídeos , Inibidores do Transportador 2 de Sódio-Glicose , Humanos , Compostos Benzidrílicos/uso terapêutico , Compostos Benzidrílicos/efeitos adversos , Glucosídeos/uso terapêutico , Glucosídeos/efeitos adversos , Masculino , Feminino , Pessoa de Meia-Idade , Inibidores do Transportador 2 de Sódio-Glicose/uso terapêutico , Inibidores do Transportador 2 de Sódio-Glicose/efeitos adversos , Idoso , Diabetes Mellitus Tipo 2/mortalidade , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/tratamento farmacológico , Diabetes Mellitus Tipo 2/fisiopatologia , Resultado do Tratamento , Fatores de Tempo , Potenciais de Ação/efeitos dos fármacos , Arritmias Cardíacas/mortalidade , Arritmias Cardíacas/diagnóstico , Arritmias Cardíacas/fisiopatologia , Frequência Cardíaca/efeitos dos fármacos , Doença das Coronárias/mortalidade , Doença das Coronárias/fisiopatologia , Doença das Coronárias/tratamento farmacológico , Doença das Coronárias/diagnóstico , Eletrocardiografia , Fatores de RiscoRESUMO
BACKGROUND AND AIM: To study the relationships of an Atherogenicity Index (ATI) and a Thrombogenicity Index (THI), with 50-year mortality from coronary heart disease (CHD), other heart diseases of uncertain etiology (HDUE) and cerebrovascular disease or stroke (STR), in 16 international cohorts of middle-aged men. METHODS AND RESULTS: Foods from a dietary survey in subsamples of men in each cohort of the Seven Countries Study (SCS) were chemically analyzed for several types of fatty acids that were converted into ATI and THI identifying each of 16 cohorts. Ecological correlations of the ATI and THI were calculated with the three fatal CVD conditions and with all-cause mortality at 25 and 50 years. Correlation coefficients (Rs) were positive and highly significant between ATI and THI versus CHD mortality, with levels ranging from 0.79 to 0.97, depending on the duration of follow-up and the choice of 10 or of 16 cohorts. This was not the case for HDUE and STR mortality for which Rs were variable and not significant. A strong direct association was also found with all-causes deaths at 25 and 50-years. ATI and THI were also directly related with dietary saturated fat and cholesterol levels and inversely with the Mediterranean Adequacy Index (a score identifying the Mediterranean diet). CONCLUSION: These findings indicate that CHD has a different relationship with dietary lipids intake than HDUE and STR. This suggests that HDUE and STR have different underlying pathways or are different diseases.
Assuntos
Aterosclerose , Humanos , Masculino , Pessoa de Meia-Idade , Seguimentos , Fatores de Tempo , Medição de Risco , Adulto , Europa (Continente)/epidemiologia , Aterosclerose/mortalidade , Aterosclerose/epidemiologia , Dieta/efeitos adversos , Dieta/mortalidade , Gorduras na Dieta/efeitos adversos , Causas de Morte , Doença das Coronárias/mortalidade , Doença das Coronárias/diagnóstico , Ácidos Graxos/efeitos adversos , Fatores de Risco , Doenças Cardiovasculares/mortalidade , Doenças Cardiovasculares/diagnóstico , Acidente Vascular Cerebral/mortalidade , Transtornos Cerebrovasculares/mortalidadeRESUMO
BACKGROUND: The health outcomes and their adherence to guideline-based secondary prevention physical activity in US patients with coronary heart disease (CHD), together with the association between physical activity (PA) and mortality risk, were investigated. METHODS: Data on CHD patients (aged 18 to 85 years) was acquired from the US National Health and Nutrition Examination Survey (NHANES) 1999-2018. The patients were divided into four groups according to the level and frequency of PA, namely, a) sedentary (n = 1178), b) moderate PA (moderate, n = 270), c) vigorous PA once or twice per week (vigorous ≤2×, n = 206), and d) vigorous PA three or more times per week (vigorous >2×, n = 598). Logistic analysis was used to determine the relationship between PA and all-cause or cardio-cerebrovascular mortality in CHD patients. RESULTS: A total of 2252 patients with CHD were enrolled, of whom 47.69% reported adequate PA. During the investigation, there were 296 (13.14%) cardio-cerebrovascular and 724 (32.15%) all-cause deaths. The incidence of all-cause or cardio-cerebrovascular death was lowest in the vigorous ≤2× group. Patients who undertook vigorous PA ≤ 2× showed the lowest risk of all-cause (odds ratio 0.32; 95% confidence interval 0.22-0.47; P < 0.01) or cardio-cerebrovascular death (odds ratio 0.43; 95% confidence interval 0.25-0.73; P < 0.01) relative to those in the sedentary group. More frequent vigorous PA did not lead to improved benefits. CONCLUSIONS: Vigorous PA once or twice per week was more effective for reducing all-cause and cardio-cerebrovascular mortality compared with patients performing no or a moderate level of PA in US adults with CHD.
Assuntos
Doença das Coronárias , Exercício Físico , Inquéritos Nutricionais , Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Adulto , Exercício Físico/fisiologia , Doença das Coronárias/mortalidade , Idoso de 80 Anos ou mais , Adulto Jovem , Adolescente , Transtornos Cerebrovasculares/mortalidade , Transtornos Cerebrovasculares/prevenção & controle , Estados Unidos/epidemiologia , Causas de Morte/tendênciasRESUMO
BACKGROUND AND AIMS: Our study examined the trends of cardiovascular health metrics in individuals with coronary heart disease (CHD) and their associations with all-cause and cardiovascular disease mortality in the US. METHODS AND RESULTS: The cohort study was conducted based on the National Health and Nutrition Examination Survey 1999-2018 and their linked mortality files (through 2019). Baseline CHD was defined as a composite of self-reported doctor-diagnosed coronary heart disease, myocardial infarction, and angina pectoris. Cardiovascular health metrics were assessed according to the American Heart Association recommendations. Long-term all-cause and cardiovascular disease mortality were the primary outcomes. Survey-adjusted Cox regression models were used to estimate hazard ratios and corresponding 95% confidence intervals for the associations between cardiovascular health metrics and all-cause and cardiovascular disease mortality. The prevalence of one or fewer ideal cardiovascular health metrics increased from 14.15% to 22.79% (P < 0.001) in CHD, while the prevalence of more than four ideal cardiovascular health metrics decreased from 21.65% to 15.70 % (P < 0.001) from 1999 to 2018, respectively. Compared with CHD participants with one or fewer ideal cardiovascular health metrics, those with four or more ideal cardiovascular health metrics had a 35% lower risk (hazard ratio, 0.65; 95% confidence interval: 0.51, 0.82) and a 44% lower risk (0.56; 0.38, 0.84) in all-cause and cardiovascular disease mortality, respectively. CONCLUSION: Substantial declines were noted in ideal cardiovascular health metrics in US adults with CHD. A higher number of cardiovascular health metrics was associated with lower all-cause and cardiovascular disease mortality in them.
Assuntos
Causas de Morte , Doença das Coronárias , Inquéritos Nutricionais , Humanos , Masculino , Feminino , Estados Unidos/epidemiologia , Pessoa de Meia-Idade , Doença das Coronárias/mortalidade , Doença das Coronárias/diagnóstico , Doença das Coronárias/epidemiologia , Fatores de Tempo , Idoso , Medição de Risco , Adulto , Prognóstico , Nível de Saúde , Prevalência , Fatores de Proteção , Fatores de Risco , Fatores de Risco de Doenças Cardíacas , Indicadores Básicos de Saúde , Comportamento de Redução do RiscoRESUMO
BACKGROUND: To investigate the relationship between egg consumption and mortality in individuals with pre-existing coronary heart disease or stroke. METHODS: This study utilized data from the National Health and Nutrition Examination Survey conducted between 1999 and 2018. Egg consumption was evaluated through 24 h dietary recalls at baseline. Mortality status was tracked until December 31, 2019. Survey-weighted Cox proportional hazards models were utilized. RESULTS: The study involved 3,975 participants aged 20 years or older with a median follow-up of 89.00 months. A total of 1,675 individuals died during follow-up. Compared to individuals who did not consume eggs, the consumption of 0-50 g/day (hazard ratio [HR] = 1.033, 95% confidence interval [CI] =0.878-1.214) was not found to have a significant association with all-cause mortality. However, consuming 50-100 g/day (HR = 1.281, 95% CI = 1.004-1.635) and >100 g/day (HR = 1.312, 95% CI =1.036-1.661) exhibited a significant association with an increased risk of all-cause mortality. We identified a non-liner relationship between egg consumption and cardiovascular mortality, where the risk was found to be lowest at an intake of about 50 g/day. For individuals consuming more than 50 g/day, each additional 50 g increment in egg consumption was significantly linked to an elevated risk of cardiovascular mortality (HR = 1.276, 95% CI = 1.009-1.614). CONCLUSION: In U.S. adults with pre-existing cardiovascular disease, a significant positive association was found between consuming over 50 g of eggs per day and the risk of mortality, highlighting the importance of moderate intake.
Assuntos
Doença das Coronárias , Ovos , Inquéritos Nutricionais , Acidente Vascular Cerebral , Humanos , Feminino , Masculino , Estados Unidos/epidemiologia , Pessoa de Meia-Idade , Doença das Coronárias/mortalidade , Doença das Coronárias/epidemiologia , Adulto , Acidente Vascular Cerebral/mortalidade , Acidente Vascular Cerebral/epidemiologia , Idoso , Estudos de Coortes , Dieta/estatística & dados numéricos , Fatores de Risco , Modelos de Riscos ProporcionaisRESUMO
BACKGROUND: The triglyceride glucose-body mass index (TyG-BMI) is recognized as a reliable surrogate for evaluating insulin resistance and an effective predictor of cardiovascular disease. However, the link between TyG-BMI index and adverse outcomes in heart failure (HF) patients remains unclear. This study examines the correlation of the TyG-BMI index with long-term adverse outcomes in HF patients with coronary heart disease (CHD). METHODS: This single-center, prospective cohort study included 823 HF patients with CHD. The TyG-BMI index was calculated as follows: ln [fasting triglyceride (mg/dL) × fasting blood glucose (mg/dL)/2] × BMI. To explore the association between the TyG-BMI index and the occurrences of all-cause mortality and HF rehospitalization, we utilized multivariate Cox regression models and restricted cubic splines with threshold analysis. RESULTS: Over a follow-up period of 9.4 years, 425 patients died, and 484 were rehospitalized due to HF. Threshold analysis revealed a significant reverse "J"-shaped relationship between the TyG-BMI index and all-cause mortality, indicating a decreased risk of all-cause mortality with higher TyG-BMI index values below 240.0 (adjusted model: HR 0.90, 95% CI 0.86-0.93; Log-likelihood ratio p = 0.003). A distinct "U"-shaped nonlinear relationship was observed with HF rehospitalization, with the inflection point at 228.56 (adjusted model: below: HR 0.95, 95% CI 0.91-0.98; above: HR 1.08, 95% CI 1.03-1.13; Log-likelihood ratio p < 0.001). CONCLUSIONS: This study reveals a nonlinear association between the TyG-BMI index and both all-cause mortality and HF rehospitalization in HF patients with CHD, positioning the TyG-BMI index as a significant prognostic marker in this population.
Assuntos
Biomarcadores , Glicemia , Índice de Massa Corporal , Doença das Coronárias , Insuficiência Cardíaca , Readmissão do Paciente , Triglicerídeos , Humanos , Masculino , Feminino , Insuficiência Cardíaca/mortalidade , Insuficiência Cardíaca/sangue , Insuficiência Cardíaca/diagnóstico , Triglicerídeos/sangue , Pessoa de Meia-Idade , Idoso , Estudos Prospectivos , Glicemia/metabolismo , Fatores de Tempo , Biomarcadores/sangue , Medição de Risco , Fatores de Risco , Doença das Coronárias/mortalidade , Doença das Coronárias/sangue , Doença das Coronárias/diagnóstico , Doença das Coronárias/epidemiologia , Prognóstico , Causas de Morte , Resistência à Insulina , Valor Preditivo dos TestesRESUMO
Addressing sex differences and disparities in coronary heart disease (CHD) involves achieving both horizontal and vertical equity in healthcare. Horizontal equity in the context of CHD means that both men and women with comparable health statuses should have equal access to diagnosis, treatment, and management of CHD. To achieve this, it is crucial to promote awareness among the general public about the signs and symptoms of CHD in both sexes, so that both women and men may seek timely medical attention. Women often face inequity in the treatment of cardiovascular disease. Current guidelines do not differ based on sex, but their applications based on gender do differ. Vertical equity means tailoring healthcare to allow equitable care for all. Steps towards achieving this include developing treatment protocols and guidelines that consider the unique aspects of CHD in women. It also requires implementing guidelines equally, when there is not sex difference rather than inequities in application of guideline directed care.
Assuntos
Disparidades em Assistência à Saúde , Humanos , Feminino , Masculino , Fatores Sexuais , Disparidades nos Níveis de Saúde , Acessibilidade aos Serviços de Saúde , Guias de Prática Clínica como Assunto , Doenças Cardiovasculares/mortalidade , Doenças Cardiovasculares/terapia , Doença das Coronárias/mortalidade , Doença das Coronárias/terapia , Doença das Coronárias/diagnóstico , Equidade em SaúdeRESUMO
BACKGROUND: Contrary to clinical guidelines, there has been a decrease over time in estrogen therapy use in premenopausal women undergoing bilateral oophorectomy for benign indications. OBJECTIVE: This study aimed to estimate the excess morbidity and mortality associated with current patterns of estrogen therapy use in women who undergo bilateral oophorectomy with hysterectomy for benign indications. STUDY DESIGN: We developed 2 Bayesian sampling Markov state-transition models to estimate the excess disease incidence (incidence model) and mortality (mortality model). The starting cohort for both models were women who had undergone bilateral oophorectomy with hysterectomy for benign indications at the age of 45 to 49 years. The models tracked outcomes in 5-year intervals for 25 years. The incidence model estimated excess incidence of breast cancer, lung cancer, colorectal cancer, coronary heart disease, and stroke, whereas the mortality model estimated excess mortality due to breast cancer, lung cancer, coronary heart disease, and all-other-cause mortality. The models compared current rates of estrogen therapy use with optimal (100%) use and calculated the mean difference in each simulated outcome to determine excess disease incidence and death. RESULTS: By 25 years after bilateral oophorectomy with hysterectomy, there were an estimated 94 (95% confidence interval, -158 to -23) fewer colorectal cancer cases, 658 (95% confidence interval, 339-1025) more coronary heart disease cases, and 881 (95% confidence interval, 402-1483) more stroke cases. By 25 years after bilateral oophorectomy with hysterectomy, there were an estimated 189 (95% confidence interval, 59-387) more breast cancer deaths, 380 (95% confidence interval, 114-792) more coronary heart disease deaths, and 759 (95% confidence interval, 307-1527) more all-other-cause deaths. In sensitivity analyses where we defined estrogen therapy use as a duration of >2 years of use, these differences increased >2-fold. CONCLUSION: Underuse of estrogen therapy in premenopausal women who undergo oophorectomy is associated with substantial excess morbidity and mortality.
Assuntos
Neoplasias da Mama , Terapia de Reposição de Estrogênios , Histerectomia , Ovariectomia , Pré-Menopausa , Humanos , Feminino , Pessoa de Meia-Idade , Neoplasias da Mama/mortalidade , Neoplasias da Mama/cirurgia , Teorema de Bayes , Neoplasias Colorretais/mortalidade , Neoplasias Colorretais/cirurgia , Acidente Vascular Cerebral/epidemiologia , Incidência , Cadeias de Markov , Neoplasias Pulmonares/mortalidade , Neoplasias Pulmonares/cirurgia , Doença das Coronárias/mortalidade , Doença das Coronárias/epidemiologiaRESUMO
Introducción: La asociación entre la retinopatía hipertensiva y cardiopatías coronarias es un tema de una larga controversia. La retinopatía hipertensiva ha sido definida como un predictor de mortalidad y morbilidad en pacientes hipertensos desde hace mucho tiempo. Además, estudios recientes han demostrado que la microvasculatura retiniana refleja la patología en los pequeños vasos sistémicos, incluida la microcirculación coronaria. Objetivos: El objetivo fue realizar una revisión sistemática y un análisis cualitativo y cuantitativo mediante un metanálisis para determinar la asociación entre la retinopatía hipertensiva y cardiopatías coronarias. Métodos: Se realizó la búsqueda sistemática de estudios relacionados con el tema. La fuente de búsqueda fue PubMed y Google Scholar. La revisión sistemática y meta-análisis se desarrollaron con las pautas Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA). Resultados: Se demostró que existe una asociación entre la retinopatía hipertensiva y la enfermedad de la arteria coronaria. (P=0,01; RR 1,29; IC 95 por ciento: 1,06 a 1,56), se evaluó la hipertrofia ventricular izquierda como desenlace, se encontró un efecto estadísticamente significativo que asocia a la retinopatía hipertensiva con la hipertrofia ventricular izquierda (p=0,03; RR: 1,71; IC 95 por ciento: 1,31 a 2,24). Conclusiones: Se encontró asociación entre retinopatía hipertensiva y las cardiopatías coronarias más frecuentes (Enfermedad coronaria e HVI)(AU)
Introduction: The association between hypertensive retinopathy and coronary heart disease is a subject of long-standing controversy. Hypertensive retinopathy has long been defined as a predictor of mortality and morbidity in hypertensive patients. In addition, recent studies have shown that the retinal microvasculature reflects pathology in small systemic vessels, including the coronary microcirculation. Objectives: The aim was to perform a systematic review and a qualitative and quantitative analysis by meta-analysis to determine the association between hypertensive retinopathy and coronary heart disease. Methods: A systematic search for studies related to the topic was performed. The search source was PubMed and Google Scholar. The systematic review and meta-analysis were developed using the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. Results: An association between hypertensive retinopathy and coronary artery disease was demonstrated (P=0.01; RR 1.29; 95 percent CI: 1.06 to 1.56), left ventricular hypertrophy was evaluated as an outcome, a statistically significant effect was found associating hypertensive retinopathy with left ventricular hypertrophy (P=0.03; RR: 1.71; 95 percent CI: 1.31 to 2.24). Conclusions: An association was found between hypertensive retinopathy and the most frequent coronary heart diseases (coronary artery disease and LVH)(AU)
Assuntos
Humanos , Masculino , Feminino , Doença das Coronárias/mortalidade , Retinopatia Hipertensiva/mortalidade , Estudos TransversaisAssuntos
Humanos , Isquemia Miocárdica/tratamento farmacológico , Doença das Coronárias/mortalidade , Doença das Coronárias/prevenção & controle , Doença das Coronárias/terapia , Metabolismo dos Lipídeos , Infarto do Miocárdio/tratamento farmacológico , Trimetazidina/efeitos adversos , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Inibidores da Agregação Plaquetária/uso terapêutico , Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem , Ivabradina/efeitos adversos , LDL-Colesterol/metabolismo , Anticoagulantes/administração & dosagem , Nitratos/efeitos adversosRESUMO
ABSTRACT Objective: Evaluate the impact of anxiety and depression on morbidity and mortality of patients with acute coronary syndrome. Method: Retrospective cohort study, with follow-up of two years, conducted with 94 patients. The morbidity and mortality (readmission, myocardial revascularization, and death) was evaluated immediately after discharge and after one and two years. Anxiety and depression were evaluated by the State-Trait Anxiety Inventory and by Beck's Depression Inventory. The Kaplan-Meier estimator and the Logrank test were used. The significance level adopted was 0.05. Results: We observed that 76.6% of the patients did not present symptoms of depression or had mild signs, while 78.8% had low to moderate anxiety. The symptoms of depression and anxiety were not related to morbidity (need for MR p=0.098 and 0.56, respectively; readmission p=0.962 and 0.369, respectively) and mortality (p=0.434 and 0.077, respectively). Conclusion: No relationship was found between levels of anxiety and depression with the morbidity and mortality of patients.
RESUMEN Objetivo: Evaluar el impacto de la ansiedad y de la depresión en la morbimortalidad de pacientes con síndrome coronaria aguda. Método: Estudio de cohorte retrospectivo, con seguimiento de dos años, ha sido realizado con 94 pacientes. La morbimortalidad (la readmisión, la revascularización del miocardio y del óbito) ha sido evaluada inmediatamente después del alta hospitalaria y después de uno y dos años. La ansiedad y la depresión han sido evaluadas por el Inventario de Ansiedad Trazo y por el Inventario de Depresión de Beck. Se ha utilizado de los gráficos de Kaplan-Meier y de la prueba Logrank. El nivel de significancia que ha sido adoptado ha sido de 0,05. Resultados: Se ha observado que el 76,6% de los pacientes no presentaban síntomas de depresión o presentaban señales leves y el 78,8% tenían ansiedad de baja a moderada. Los síntomas de depresión y de ansiedad no se han relacionado a la morbilidad (necesidad de RM p=0,098 y 0,56, respectivamente; readmisión p=0,962 y 0,369, respectivamente) y a la mortandad (p=0,434 y 0,077, respectivamente). Conclusión: No hubo relación entre niveles de ansiedad y depresión con la morbimortalidad de los pacientes.
RESUMO Objetivo: Avaliar o impacto da ansiedade e depressão na morbimortalidade de pacientes com síndrome coronariana aguda. Método: Estudo de coorte retrospectivo, com seguimento de dois anos, realizado com 94 pacientes. A morbimortalidade (readmissão, revascularização do miocárdio e óbito) foi avaliada imediatamente após a alta hospitalar e depois de um e dois anos. A ansiedade e a depressão foram avaliadas pelo Inventário de Ansiedade Traço e pelo Inventário de Depressão de Beck. Utilizou-se dos gráficos de Kaplan-Meier e do teste Logrank. O nível de significância adotado foi de 0,05. Resultados: Observou-se que 76,6% dos pacientes não apresentavam sintomas de depressão ou apresentavam sinais leves e 78,8% tinham ansiedade baixa a moderada. Os sintomas de depressão e ansiedade não se relacionaram à morbidade (necessidade de RM p=0,098 e 0,56, respectivamente; readmissão p=0,962 e 0,369, respectivamente) e à mortalidade (p=0,434 e 0,077, respectivamente). Conclusão: Não houve relação entre níveis de ansiedade e depressão com a morbimortalidade dos pacientes.
Assuntos
Humanos , Masculino , Feminino , Adulto , Idoso , Ansiedade/complicações , Morbidade , Doença das Coronárias/psicologia , Depressão/complicações , Ansiedade/psicologia , Estudos Retrospectivos , Doença das Coronárias/complicações , Doença das Coronárias/mortalidade , Depressão/psicologia , Pessoa de Meia-IdadeRESUMO
Abstract Objective: To report the early results of the BYPASS project - the Brazilian registrY of adult Patient undergoing cArdiovaScular Surgery - a national, observational, prospective, and longitudinal follow-up registry, aiming to chart a profile of patients undergoing cardiovascular surgery in Brazil, assessing the data harvested from the initial 1,722 patients. Methods: Data collection involved institutions throughout the whole country, comprising 17 centers in 4 regions: Southeast (8), Northeast (5), South (3), and Center-West (1). The study population consists of patients over 18 years of age, and the types of operations recorded were: coronary artery bypass graft (CABG), mitral valve, aortic valve (either conventional or transcatheter), surgical correction of atrial fibrillation, cardiac transplantation, mechanical circulatory support and congenital heart diseases in adults. Results: 83.1% of patients came from the public health system (SUS), 9.6% from the supplemental (private insurance) healthcare systems; and 7.3% from private (out-of -pocket) clinic. Male patients comprised 66%, 30% were diabetics, 46% had dyslipidemia, 28% previously sustained a myocardial infarction, and 9.4% underwent prior cardiovascular surgery. Patients underwent coronary artery bypass surgery were 54.1% and 31.5% to valve surgery, either isolated or combined. The overall postoperative mortality up to the 7th postoperative day was 4%; for CABG was 2.6%, and for valve operations, 4.4%. Conclusion: This first report outlines the consecution of the Brazilian surgical cardiac database, intended to serve primarily as a tool for providing information for clinical improvement and patient safety and constitute a basis for production of research protocols.
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Procedimentos Cirúrgicos Cardiovasculares/estatística & dados numéricos , Sistema de Registros/estatística & dados numéricos , Estudos Multicêntricos como Assunto/estatística & dados numéricos , Bases de Dados Factuais/estatística & dados numéricos , Procedimentos Cirúrgicos Cardiovasculares/mortalidade , Brasil/epidemiologia , Ponte de Artéria Coronária/mortalidade , Ponte de Artéria Coronária/estatística & dados numéricos , Estudos Prospectivos , Resultado do Tratamento , Doença das Coronárias/cirurgia , Doença das Coronárias/mortalidade , Valvas Cardíacas/cirurgiaRESUMO
La muerte súbita de un atleta o deportista siempre es un hecho trágico de gran exposición mediática, que genera gran impacto social. Afortunadamente es un hecho extremadamente raro que tiene una incidencia entre 1:80 000 y 1:200 000 atletas/año. Sus causas son distintas de acuerdo con la edad del atleta o deportista. En aquellos menores de 35 años predominan las miocardiopatías y las anomalías congénitas de las arterias coronarias; en los mayores de 35 años, la principal causa es la enfermedad coronaria aterosclerótica adquirida. Es común para ambos grupos la muerte súbita arrítmica con corazón estructuralmente normal. La tarea del equipo de salud que asiste a esta población reside en conocer y detectar las potenciales causas para restringir la participación en el deporte de los atletas en riesgo (prevención primaria). Pero también debemos estar preparados para asistir las muertes súbitas de los atletas en el campo de juego con programas de asistencia para emergencias cardiovasculares que incluyan desfibriladores externos automáticos (prevención secundaria). (AU)
The sudden death of an athlete is always a tragic event that leads to a great media exposure that generates great social impact. Fortunately, it is an extremely rare event with an incidence of 1: 80,000 to 1: 200,000 athletes per year. The causes vary according to the age of the athlete. In those < 35 years old, predominantly cardiomyopathies, and congenital anomalies of the coronary arteries. Whereas in the > 35 years, the main cause is generally acquired atherosclerotic coronary disease. In both groups, it is common to experience arrhythmic sudden death despite having a structurally normal heart. It is the task of the health teams that treat this population to know and detect potential causes to restrict participation in sport for the athletes at risk (primary prevention). But we must also be prepared to attend sudden deaths of athletes in the field with assistance programs for cardiovascular emergencies including automated external defibrillators (secondary prevention). (AU)